![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Emergex Partners with Brazil’s Bio-Manguinhos to Develop COVID-19 Vaccine
Emergex Partners with Brazil’s Bio-Manguinhos to Develop COVID-19 Vaccine
January 7, 2021
Emergex and Brazil’s Institute of Technology on Immunobiologicals (Bio-Manguinhos) have agreed to work together on “certain immunotherapeutic programs,” including a COVID-19 vaccine.
Emergex will support studies, including clinical trials, and will manufacture, market, promote and distribute certain vaccines within Brazil’s National Health Service, the UK company said.
The COVID-19 vaccine they will co-develop will use Emergex’s synthetic T-Cell vaccine technology. Financial details of the agreement were not disclosed.
Upcoming Events
-
21Oct